Clinical trial · Interventional
Circulating Tumor Cells Spillage After Pulmonary Biopsy
NCT02507778CI-TRIAL-00024020unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to quantify the spillage of tumor cells after biopsy in early lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CellCollectorTM (Gilupi, Germany) needle | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- biopsy
- description
- needle will be inserted before and after biopsy and will measure circulating tumor cells.
- interventionNames
- Device: CellCollectorTM (Gilupi, Germany) needle
Primary outcomes (1)
- measure
- Circulating tumor cells (CTCs) before and after the procedure.
- timeFrame
- 1 day
- description
- In this study we will use for CTC counting the CellCollectorTM (Gilupi, Germany) needle that isolates CTCs of epithelial origin using a needle coated with antibodies directed against the epithelial cell adhesion molecules (EpCAM).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * A diagnosis of lung cancer * Patients are designated to undertake biopsy * Able and willing to participate in this study * Availability of a signed informed consent Exclusion Criteria: * Any recent non-lung cancer in the recent 2 years.
References
Publications (0)
Data not yet available
No reference posted for this study.